Newsroom

All Actos bladder cancer cases that were part of the Multi-District Litigation (“MDL”) involving use of Actos prior to Dec. 1, 2011, and most other Actos cases filed elsewhere,  were settled as of April 28, 2015.  This includes all Actos clients who had retained Locks Law Firm to represent them as of that date.  The settlement includes nearly 9,000 cases for a total of $2.4 billion.  Completed claims packages with all required supporting documentation must be submitted by January 8, 2016.  The Locks Law Firm pharmaceutical team has been working diligently to meet this deadline and ensure that all of our Actos clients receive the highest possible offers.  It is not known how long it will take for all of the cases to be processed and paid, but we are hopeful that everything will be concluded in 2016.  Locks Law Firm continues to accept Actos cases for persons who used Actos prior to Dec. 1, 2011 and were diagnosed with bladder cancer within the last two years.

The Locks Law Firm is now investigating claims against e-cigarette "juice" manufacturers.  A recent Harvard study revealed that a number of manufacturers were selling juices which contained diacetyl and other chemicals without indicating the presence of those chemicals or including warnings related to those chemicals on their labels.  Two of the manufacturers in the study specifically represented that their products were "diacetyl free," while the Harvard study seems to indicate that the products did contain diacetyl.

This month the Food and Drug Administration (FDA) has added new warnings to the Type 2 diabetes medications known as SGLT2 Inhibitors.  In May of 20-15 FDA issued warnings that the use of these drugs could cause too much acid to be present in the blood, a condition called ketoacidosis. The updated warnings issued in December 2015 reinforce that patients and their doctors should be on the look-out for signs and symptoms of ketoacidosis which include nausea, vomiting, abdominal pain, tiredness and trouble breathing.